Results 31 to 40 of about 5,337 (191)
CPT: Pharmacometrics & Systems Pharmacology, 2022 Aducanumab is a human immunoglobulin G1 anti‐amyloid beta (Aβ) antibody currently being evaluated for potential treatment of patients with early Alzheimer’s disease.
Kumar Kandadi Muralidharan +6 more
doaj +1 more source
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
Brain Sciences, 2021 Correct in vivo diagnosis of Alzheimer’s disease (AD) helps to avoid administration of disease-modifying treatments in non-AD patients, and allows the possible use of such treatments in clinically atypical AD patients.
George P. Paraskevas, Elisabeth Kapaki
doaj +1 more source
Aducanumab- a Drug of hope for the elderly
Journal of the Pakistan Medical Association, 2022 Madam, Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by impaired cognitive functions in a person (1). It is the most common cause of dementia and a major cause of morbidity and mortality in the elderly. Currently, 50 million people in the world live with dementia, AD accounting for more than half (50-75%) of all ...
Muhammad Kashan, Zaheer +2 more
openaire +2 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2022 Alzheimer's disease (AD) is an irreversible, progressive brain disorder that impairs memory and cognitive function. Dysregulation of the amyloid‐β (Aβ) pathway and amyloid plaque accumulation in the brain are hallmarks of AD.
Lin Lin +9 more
doaj +1 more source
Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament? [PDF]
, 2022 When the FDA granted accelerated approval of Biogen's Alzheimer disease drug, aducanumab (marketed as Aduhelm), it deviated from its mission of guaranteeing drug safety and efficacy because the approval was based exclusively on a perceived dose-dependent
Alavi, Abass +4 more
core +1 more source
Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review [PDF]
, 2022 Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role as caregiver.
Haddad, Hannah +7 more
core +1 more source
Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease [PDF]
Farmacja Polska, 2023 Alzheimer's disease (AD) is the most common cause of dementia worldwide. According to the widely accepted theory, it is caused by neurodegeneration initiated by the deposition of a pathological protein, amyloid β, in the brain. Amyloid β can aggregate to
Jakub Wojcieszak
doaj +1 more source
How Will Aducanumab Approval Impact AD Research?
, 2021 This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Saykin, A. J. +13 more
core +1 more source
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Clinical Interventions in Aging, 2022 Miguel Vaz,1 Vítor Silva,1 Cristina Monteiro,2 Samuel Silvestre1,3 1CICS-UBI - Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, Covilhã, 6200-506, Portugal; 2UFBI – Pharmacovigilance Unit of Beira Interior ...
Vaz M, Silva V, Monteiro C, Silvestre S
doaj
Alzheimer's disease drug development pipeline: 2022
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022 Introduction Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs
Jeffrey Cummings +6 more
doaj +1 more source